Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of “Hold” by Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has been assigned an average rating of “Hold” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $4.50.

A number of analysts have issued reports on GOSS shares. Weiss Ratings lowered Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. HC Wainwright cut their price objective on shares of Gossamer Bio from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, June 25th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a research report on Monday, March 23rd.

Gossamer Bio Stock Performance

NASDAQ GOSS traded down $0.01 during mid-day trading on Tuesday, reaching $0.18. 6,518,759 shares of the stock were exchanged, compared to its average volume of 13,813,055. Gossamer Bio has a 1-year low of $0.14 and a 1-year high of $3.87. The stock has a market capitalization of $42.48 million, a PE ratio of -0.23 and a beta of 2.04. The business’s fifty day simple moving average is $0.23 and its 200 day simple moving average is $1.12.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $16.95 million during the quarter, compared to analyst estimates of $4.67 million. On average, analysts anticipate that Gossamer Bio will post -0.37 EPS for the current year.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings in shares of Gossamer Bio by 66.5% during the 1st quarter. Bank of America Corp DE now owns 3,173,725 shares of the company’s stock worth $1,041,000 after buying an additional 1,267,056 shares during the last quarter. ADAR1 Capital Management LLC raised its position in shares of Gossamer Bio by 233.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 287,531 shares of the company’s stock worth $94,000 after buying an additional 503,100 shares during the period. Kalehua Capital Management LLC acquired a new position in Gossamer Bio in the first quarter valued at $3,363,000. Renaissance Technologies LLC grew its position in Gossamer Bio by 84.8% during the first quarter. Renaissance Technologies LLC now owns 1,217,868 shares of the company’s stock valued at $400,000 after acquiring an additional 558,980 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Gossamer Bio during the first quarter valued at about $38,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.